Prostate cancer in 2025: screening and treatments are changing

In the waiting room, the word “prostate” is still often spoken quietly. A 62-year-old man studies his PSA prescription, while his partner turns the pages of a magazine without really reading it; both are thinking about the question nobody initially dares to ask: “What if it is serious?” In 2025, this scene remains common in urology and oncology clinics, yet the answers have evolved. A blood test is no longer expected to determine everything on its own, MRI can sometimes spare patients unnecessary biopsies, and some treatments now target tumour cells with unprecedented precision. Prostate cancer is no longer treated in quite the same way as it was ten years ago. That shift can make a significant difference.

Prostate cancer: screening is finally moving beyond PSA alone

For many years, screening came down to a blood sample and one figure: PSA. However, this marker can rise for several, sometimes harmless, reasons, including inflammation, a urinary infection or age-related enlargement of the prostate. In 2025, specialists place greater emphasis on the wider picture: age, family history, ancestry, changes in PSA over time and any symptoms. A raised result is not a verdict. It is a warning sign that needs to be assessed calmly and methodically in context.

In many centres, a prostate MRI is now offered before biopsy when a risk is suspected. It can show suspicious areas and enables samples to be taken more accurately. A major European study, frequently mentioned during consultations, found that this approach could spare some men a biopsy while identifying significant cancers more effectively. MRI before biopsy does not remove every uncertainty, but it reduces the blind process that caused so much anxiety for patients.

Biological tools are also becoming more widely used: PSA density, the PHI score, the 4Kscore test and genetic analyses in certain specific circumstances. They do not replace the doctor; they help them assess the genuine likelihood of an aggressive cancer. This distinction matters because many prostate tumours grow very slowly and do not pose an immediate threat to life. Better detection therefore does not mean more treatment. The challenge in 2025 is more nuanced: identifying those who need a prompt response without turning everyone else into worried patients for years.

MRI, targeted biopsy and genetics: what patients can ask for in 2025

When PSA is abnormal, a useful first step is to ask whether the result should be checked again before any decision is made. A recent infection, sexual activity, intensive cycling or manipulation of the prostate can sometimes affect the level; the doctor will judge each situation individually. It is also worth asking whether a multiparametric MRI is appropriate before a biopsy. Let us be honest: hardly anyone does this every day, reading their medical results with perspective. Even so, arriving at an appointment with two or three written questions can alter the discussion.

A common mistake is to assume that a detected cancer must be removed or treated with radiotherapy immediately. For localised low-risk tumours, active surveillance is often a sound option, monitored through regular PSA tests, MRI scans and occasionally further biopsies. It does not mean “doing nothing”. Above all, it helps avoid the side effects of premature treatment, particularly those affecting erections and urinary function. Many men fear this period of waiting, which is entirely understandable: living with a diagnosis can sometimes require more courage than undergoing immediate intervention.

Where there is a strong family history involving several cases of prostate, breast, ovarian or pancreatic cancer, a cancer genetics consultation may be offered. Mutations in genes such as BRCA1, BRCA2 or ATM do not affect every patient, but they can guide screening for relatives and certain treatment decisions if the disease is advanced.

“The best decision is not always the most spectacular one: it is the one that matches the tumour’s risk, the patient’s age and what he wants to preserve in his daily life,” notes an oncologist specialising in urological cancers.

• Ask about the trend in PSA, rather than only its most recent value;
• Check whether an MRI can be performed before tissue samples are taken;
• Discuss active surveillance if the cancer is classed as low risk;
• Report any family history of cancer.

2025 treatments target prostate cancer more accurately while protecting daily life

For localised cancers requiring treatment, robot-assisted surgery and precision radiotherapy continue to improve. Teams are better able to tailor doses, protect neighbouring tissue and discuss potential consequences openly before a choice is made. Focal techniques, including high-intensity focused ultrasound in selected cases, offer hope, although they do not replace standard treatments for everyone. The question is no longer simply, “Can the tumour be destroyed?” It has become: can this be done while preserving intimacy, independence and comfort as far as possible?

For metastatic forms, PSMA PET imaging has transformed the map of cancer. It can reveal lesions that are sometimes invisible on conventional CT scans or bone scans, refining disease staging and treatment selection. In 2025, PSMA-targeting radioligands, including lutetium-177, are playing an increasing role in certain PSMA-expressing castration-resistant cancers. In the United States, the expanded indication for lutetium-177-PSMA-617 after hormone therapy marked 2025, offering the possibility of delaying chemotherapy for eligible patients.

Targeted therapies and drug combinations also provide new options, especially for men carrying certain DNA repair abnormalities. In clearly defined situations, PARP inhibitors may complement modern hormone therapy following discussion by a multidisciplinary team. Personalised treatment is not a marketing promise: it is based on analysing the cancer, its extent and, in some cases, its molecular profile. One simple fact remains: every innovation also brings its own demands, including blood monitoring, possible fatigue and side effects that should be anticipated with the clinical team.

These 2025 developments do not make prostate cancer a minor issue. They do, however, give doctors and patients more ways to act at a time when uncertainty can seem overwhelming. Whether it involves monitored PSA, properly interpreted MRI, targeted biopsy or a tailored treatment strategy, decisions are becoming less automatic and more personal. We all know the moment when someone close to us plays down a symptom to avoid worrying their family. Raising the subject earlier-whether of considered screening, family history or persistent urinary discomfort-may prevent many regrets. The right pathway often begins with a question asked without shame in a consulting room, to a doctor who takes the time to listen.

Key point	Detail	Added value for the reader
PSA interpreted with nuance	PSA remains useful, but a single level cannot establish a diagnosis. Its change over time, prostate size, family history and symptoms all need to be considered together. A repeat test may sometimes be suggested before moving towards more invasive investigations.	The reader understands that a high result does not automatically mean cancer. This approach helps them prepare for a consultation without panicking and request a clear explanation of their personal level of risk.
MRI and more targeted biopsies	Multiparametric MRI before biopsy can identify suspicious areas and direct sampling. In some care pathways, no worrying lesion may mean that an immediate biopsy can be avoided, depending on the overall risk assessed by the urologist.	Fewer unnecessary procedures, less uncertainty and better detection of tumours that genuinely require treatment. The patient can ask whether this approach is available at their centre.
Treatments tailored to the disease profile	Active surveillance, surgery, radiotherapy, hormone therapy, targeted medicines and PSMA radioligands do not address the same situations. The innovations of 2025 mainly concern greater precision in assessment and selected advanced forms of the disease.	The reader can better understand that there is no single “best treatment”. Personal priorities, the seriousness of the cancer and expected side effects should shape a shared decision.